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Abstract
Background: Peripheral-type benzodiazepine receptor (PBR) expression levels are low in normal human brain, but
their levels increase in inflammation, brain injury, neurodegenerative states and gliomas. It has been reported that
PBR functions as an immunomodulator. The mechanisms of action of midazolam, a benzodiazepine, in the
immune system in the CNS remain to be fully elucidated. We previously reported that interleukin (IL)-1b stimulates
IL-6 synthesis from rat C6 glioma cells and that IL-1b induces phosphorylation of inhibitory kappa B (IB), p38
mitogen-activated protein (MAP) kinase, stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK),
extracellular signal-regulated kinase 1/2, and signal transducer and activator of transcription (STAT)3. It has been
shown that p38 MAP kinase is involved in IL-1b-induced IL-6 release from these cells. In the present study, we
investigated the effect of midazolam on IL-1b-induced IL-6 release from C6 cells, and the mechanisms of this
effect.
Methods: Cultured C6 cells were stimulated by IL-1b. IL-6 release from C6 cells was measured using an enzyme-
linked immunosorbent assay, and phosphorylation of IB, the MAP kinase superfamily, and STAT3 was analyzed by
Western blotting.
Results: Midazolam, but not propofol, inhibited IL-1b-stimulated IL-6 release from C6 cells. The IL-1b-stimulated
levels of IL-6 were suppressed by wedelolactone (an inhibitor of IB kinase), SP600125 (an inhibitor of SAPK/JNK),
and JAK inhibitor I (an inhibitor of JAK 1, 2 and 3). However, IL-6 levels were not affected by PD98059 (an inhibitor
of MEK1/2). Midazolam markedly suppressed IL-1b-stimulated STAT3 phosphorylation without affecting the
phosphorylation of p38 MAP kinase, SAPK/JNK or IB.
Conclusion: These results strongly suggest that midazolam inhibits IL-1b-induced IL-6 release in rat C6 glioma cells
via suppression of STAT3 activation. Midazolam may affect immune system function in the CNS.
Background
Midazolam, a benzodiazepine, is used as an intrave-
nously administered anesthetic for premedication,
induction and maintenance of general anesthesia, and
sedation in intensive care unit patients, who sometimes
need treatment for central nervous system (CNS) dis-
eases or who have CNS complications [1]. Benzodiaze-
pine receptors consist of two types of receptors, central-
type benzodiazepine receptors (CBRs), which are
coupled to type A gamma-amminobutyric acid
(GABAA) receptors, and peripheral-type benzodiazepine
receptors (PBRs), which are not coupled to GABAA
receptors [2,3]. Although it has been demonstrated that
midazolam binds to and activates both CBRs and PBRs
[4], midazolam has a hypnotic effect that is mediated via
CBRs in neurons [1-3]. With regard to receptor expres-
sion, CBRs are expressed exclusively in the CNS [2].
Expression of CBRs coupled to GABAA receptors in
astrocytes has been shown to be influenced by astrocytic
maturation, differentiation, and activation [5]. In con-
trast, PBRs are detected in many peripheral tissues and
cells, such as kidney, endocrine organs and monocytes
[2,3]. While the expression levels of PBRs are low in
normal human brain, levels in both astrocytes and
microglia increase in conditions of glial activation; for
example, inflammation, brain injury, neurodegenerative
states, and gliomas [2,3]. C6 cells, derived from rat
glioma cells, have been shown to express PBRs and few
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of PBR functions in astrocytes.
PBRs have been reported to function in the regulation
of cellular proliferation, immunomodulation, steroido-
genesis, oxidative processes, and programmed cell death
[2,3]. Several animal studies have demonstrated that
midazolam can improve neural recovery after anoxia
and ischemia [7]. Cytokines, particularly interleukin
(IL)-1b and tumor necrosis factor (TNF)-a,a c t i v a t et h e
immune system and enhance brain damage [8]. Midazo-
lam has been shown to inhibit IL-6 mRNA expression
in human peripheral blood mononuclear cells [9], and
to suppress lipopolysachccaride (LPS)-induced nitric
oxide and TNF-a release from rat microglia via PBRs
[10]. Thus, these results led us to speculate that midazo-
lam might modulate immune system function in the
CNS. However, the exact mechanism of action of mida-
zolam effects on immune system in the CNS remain to
be fully elucidated.
In the physiological CNS, IL-1b, a pro-inflammatory
cytokine, is expressed at low levels [11-13]. IL-1 plays a
role in some physiological processes including sleep and
synaptic plasticity [12]. Levels of IL-1b increase in cere-
brospinal fluid in patients with traumatic brain injury,
stroke and neurodegenerative diseases [12]. The main
source of brain IL-1b after acute insult is microglia
[11-13]. Astrocytes also produce IL-1b in response to
such stimuli, with a time course slightly later than that
of microglia [11-13]. IL-1b induces the production of
other cytokines, such as TNF-a and IL-6, from micro-
glia and astrocytes [12,13]. We have previously reported
that IL-1b significantly induces IL-6 synthesis in C6
glioma cells [14]. Cytokines like IL-1b and IL-6 have
been implicated in neuroinflammation, astrogliosis,
brain ischemia and chronic CNS diseases [11-13,15]. In
the present study, we investigated the effect of midazo-
lam on IL-1b-induced IL-6 release from C6 cells, and
the mechanisms underlying this effect.
Methods
Materials
IL-6 enzyme-linked immunosorbent assay (ELISA) kits
and IL-1b were obtained from R&D System (Minneapo-
lis, MN). Midazolam and propofol were obtained from
Sigma-Aldrich Chemical Co. (St. Louis, MO). Wedelo-
lactone, SP600125, PD98059 and Janus family of tyro-
sine kinase (JAK) inhibitor I were obtained from
Calbiochem-Novabiochem Co. (La Jolla, CA). Phospho-
specific p38 mitogen-activated protein (MAP) kinase,
p38 MAP kinase, phospho-specific stress-activated pro-
tein kinase/c-Jun N-terminal kinase (SAPK/JNK), SAPK/
JNK, phospho-specific inhibitory kappa B (IB), IB,
phospho-specific signal transducer and activator of tran-
scription (STAT)3 and STAT3 antibodies were
purchased from Cell Signaling (Beverly, MA). Glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) antibo-
dies were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). An enhanced chemiluminescence
Western blotting detection system was obtained from
GE Healthcare UK. Ltd. (Buckinghamshire, England).
Other materials and chemicals were obtained from com-
mercial sources. Wedelolactone, SP600125, PD98059
and JAK inhibitor I were dissolved in dimethyl sulfoxide.
Propofol was dissolved in ethanol. The maximum con-
centration of dimethyl sulfoxide or ethanol was 0.1%,
which did not affect the assay for IL-6 or Western blot
analysis. The viability of cells with 0.1% dimethyl sulfox-
ide or ethanol treatment after 36 h was above 97% com-
pared to the cells without treatment by trypan blue
staining.
Cell culture
Rat C6 glioma cells, obtained from the American Type
Culture Collection (Rockville, MD), were seeded into
35-mm (5 × 10
4 cells/dish) or 90-mm (2 × 10
5 cells/
dish) diameter dishes and maintained in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal
bovine serum at 37°C in a humidified atmosphere of 5%
CO2/95% air. The medium was exchanged for serum-
free DMEM after 6 days. The cells were then used for
experiments after 24 h. The cells were pretreated with
midazolam, propofol, wedelolactone, SP600125,
PD98059 or JAK inhibitor I for 60 min before IL-1b sti-
mulation when indicated.
Assay for IL-6
Cultured cells (35-mm diameter dishes) were stimulated
with 10 ng/ml IL-1b in serum-free DMEM for 36 h. The
conditioned medium was collected at the end of the incu-
bation, and IL-6 concentration was measured using an
ELISA kit. The absorbance of each sample at 450 nm and
540 nm was measured with a Multiscan JX ELISA reader
(Thermo Labsystems, Helsinki, Finland). Absorbance was
corrected with reference to a standard curve.
Western blot analysis
Cultured cells (90-mm diameter dishes) were stimulated
with 10 ng/ml IL-1b in serum-free DMEM for the indi-
cated periods. The cells were washed twice with phos-
phate-buffered saline and then lysed and sonicated in a
lysis buffer containing 62.5 mM Tris/HCl (pH 6.8), 2%
sodium dodecyl sulfate (SDS), 50 mM dithiothreitol, and
10% glycerol. The sample was used for Western blot
analysis. The samples were separated by SDS-polyacryla-
mide gel electrophoresis using the method of Laemmli
[16] in 10% polyacrylamide gels. Western blot analysis
was performed using phospho-specific p38 MAP kinase
antibodies, p38 MAP kinase antibodies, phospho-specific
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specific IB antibodies, IB antibodies, phospho-specific
STAT3 antibodies, STAT3 antibodies or GAPDH anti-
bodies, with peroxidase-labeled antibodies raised in goat
against rabbit IgG being used as secondary antibodies.
Peroxidase activity on polyvinylidene difluoride mem-
brane was visualized on X-ray film by utilizing an
enhanced chemiluminescence Western blotting detec-
tion system.
Statistical analysis
The data were analyzed by ANOVA followed by Bonferro-
ni’s method for multiple comparisons between pairs. P <
0.05 was considered to be significant. All data are pre-
sented as the mean ± SD of triplicate determinations. Each
experiment was repeated three times with similar results.
Results
Effects of midazolam or propofol on IL-1b-induced IL-6
release from C6 cells
We previously reported that IL-1b significantly induces
IL-6 mRNA expression and stimulates IL-6 release in
C6 glioma cells [14]. Midazolam, which by itself had
little effect on IL-6 levels, significantly suppressed IL-
1b-induced IL-6 release. The suppressive effect was con-
centration-dependent between 0.3 and 3 μM( F i g u r e
1A). Midazolam (3 μM) caused a 47% inhibition of the
IL-1b effect on IL-6 release. On the other hand, propo-
fol, another intravenous anesthetic, did not affect IL-1b-
induced IL-6 release at concentrations up to 10 μM
(Figure 1B).
Effect of wedelolactone on IL-1b-induced IL-6 release
from C6 cells
It is well known that cytokines induce activation of the
IB-nuclear factor kappa B (NFB) pathway after bind-
ing to receptors [11-13]. NFBb i n d st oi t sc o n s e n s u s
sequence on a target gene promoting transcription and
upregulation of gene expression in the nucleus [17].
W ec o n f i r m e dt h a tI L - 1 b induces IB phosphorylation
and its degradation in a time-dependent manner in C6
cells [18]. Then, we next examined whether the IB-
NFB pathway is involved in IL-1b-induced IL-6
release. Wedelolactone, an inhibitor of IBk i n a s e
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Figure 1 Effects of midazolam or propofol on IL-1b-induced IL-6 release. Cultured cells were pretreated with various concentrations of
midazolam (A) or propofol (B) for 60 min, and then stimulated with 10 ng/ml IL-1b (closed circle) or vehicle (open circle) for 36 h in the
presence of midazolam or propofol. Each value represents the mean ± SD of triplicate independent determinations of a representative
experiment carried out three times. Similar results were obtained with two additional and different cell preparations. *P < 0.05 in comparison to
the value of IL-1b alone.
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lation and degradation of IBa t5 0μM in C6 cells
[18]. Wedelolactone, which alone had little effect on
the IL-6 levels, significantly inhibited IL-1b-induced
IL-6 release. The suppressive effect of wedelolactone
was concentration-dependent in the range between 1
and 50 μM (Figure 2).
Effects of SP600125 or PD98059 on IL-1b-induced IL-6
release from C6 cells
MAP kinase superfamily members such as p38 MAP
kinase, SAPK/JNK and extracellular signal-regulated
kinase (Erk) 1/2 are central elements used by mamma-
lian cells to transduce the various messages of variety of
agonists [20]. We previously reported that IL-1b signifi-
cantly induces the activation of p38 MAP kinase, SAPK/
JNK and Erk 1/2 in C6 glioma cells [18]. SB203580, a
specific inhibitor of p38 MAP kinase [21], suppresses
IL-1b-induced IL-6 release from C6 cells, suggesting
that p38 MAP kinase regulates IL-6 release [22]. To
clarify whether other MAP kinases are involved in IL-
1b-induced IL-6 release from these cells, we examined
the effects of two MAP kinase inhibitors on IL-1b-
induced IL-6 release. IL-6 release induced by IL-1b was
markedly suppressed by SP600125, a specific inhibitor of
SAPK/JNK [23], which alone had little effect on IL-6
levels (Figure 3A). The suppressive effect of SP600125
was concentration dependent between 0.3 and 10 μM.
We found that SP600125 (10 μM) remarkably attenu-
ated IL-1b-induced phosphorylation of SAPK/JNK [18].
However, PD98059, a specific inhibitor of upstream
kinase (MEK1/2) that activates Erk 1/2 [24], failed to
affect IL-1b-induced IL-6 release up to 50 μM( F i g u r e
3B). We have previously confirmed that 10 μM
PD98059 truly suppresses IL-1b-induced phosphoryla-
tion of Erk 1/2 in C6 cells [18].
Effect of JAK inhibitor I on IL-1b-induced IL-6 release
from C6 cells
The JAK-STAT pathway has an essential role in driving
a variety of biological responses to cytokines [25,26].
We previously reported that IL-1b induces activation of
S T A T 3i nC 6g l i o m ac e l l s[ 1 8 ] .I no r d e rt oc l a r i f y
whether STAT3 is involved in IL-1b-induced IL-6
release in C6 cells, we examined the effect of JAK inhi-
bitor I, an inhibitor of JAK 1, 2 and 3 [27], on IL-1b-
induced IL-6 release. JAK inhibitor I, which by itself had
little effect on the IL-6 levels, significantly suppressed
IL-1b-induced IL-6 release. The effect of JAK inhibitor I
was concentration dependent between 10 nM and 30
μM (Figure 4). In a previous study [18], we found that
JAK inhibitor I (1 μM) truly reduces IL-1b-induced
phosphorylation of STAT3 in C6 cells.
Effects of midazolam on IL-1b-induced phosphorylation of
IB, p38 MAP kinase, SAPK/JNK, and STAT3 in C6 cells
In the present study, our results suggest that IL-1b
induces IL-6 release through the IB-NFB pathway, p38
MAP kinase, SAPK/JNK and JAK-STAT3 pathway in C6
glioma cells. Finally, we investigated the action point of
midazolam in IL-1b-stimulated IL-6 release from C6
cells. Midazolam failed to affect IL-1b-induced IB, p38
MAP kinase or SAPK/JNK phosphorylation in C6 cells
(Figure 5). In contrast, midazolam (10 μM) significantly
inhibited IL-1b-induced STAT3 phosphorylation (Figure
6). Midazolam (10 μM) caused a 40% inhibition of the
IL-1b effect on STAT3 phosphorylation.
Discussion
In the present study, we find that midazolam signifi-
cantly suppresses IL-1b-induced IL-6 release from C6
glioma cells. However, propofol, another intravenous
anesthetic, failed to affect IL-1b-induced IL-6 release
from C6 cells. Then, we next investigated the
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Figure 2 Effect of wedelolactone on IL-1b-induced IL-6 release.
Cultured cells were pretreated with various concentrations of
wedelolactone for 60 min, and then stimulated with 10 ng/ml IL-1b
(closed circle) or vehicle (open circle) for 36 h in the presence of
wedelolactone. Each value represents the mean ± SD of triplicate
independent determinations of a representative experiment carried
out three times. Similar results were obtained with two additional
and different cell preparations. *P < 0.05 in comparison to the value
of IL-1b alone.
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cells. IL-1b binds its receptor, which associates with IL-
1 receptor-accessory proteins to initiate an intracellular
signaling [11-13]. NFB and the MAP kinase superfam-
ily, including p38 MAP kinase, Erk 1/2 and SAPK/JNK,
are then activated by IL-1b [11-13]. IBi sp h o s p h o r y -
lated and degradated by IKK, and subsequently NFBi s
freed from IB and translocates into the nucleus [17].
In addition, the JAK-STAT pathway is recognized to
have an important role in signaling of cytokines such as
the interleukins [25,26]. Activation of the JAK-STAT
pathway leads to rapid signaling from the cell surface to
the nucleus [25,26]. We previously reported that IL-1b
induces activation of IB, p38 MAP kinase, SAPK/JNK,
Erk 1/2 and STAT3 in C6 glioma cells [18]. SB203580, a
specific inhibitor of p38 MAP kinase [21], reportedly
reduces IL-1b-induced IL-6 release from C6 cells [22].
In the present study, IL-6 release induced by IL-1b was
suppressed by wedelolactone, an inhibitor of IKK [19],
by SP600125, a specific inhibitor of SAPK/JNK [23], and
by JAK inhibitor I, an inhibitor of JAK 1, 2 and 3 [27];
but not by PD98059, a specific inhibitor of MEK1/2
[24]. Therefore, based on these findings, it is probable
that IL-1b induces IL-6 release through activation of the
IB-NFB pathway, p38 MAP kinase, SAPK/JNK and
JAK-STAT3 pathway in C6 glioma cells. These results
are consistent with our previous report, in which we
found that TNF-a induces IL-6 release through the IB-
NFB pathway, p38 MAP kinase, SAPK/JNK and the
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Figure 3 Effects of SP600125 or PD98059 on IL-1b-induced IL-6 release. Cultured cells were pretreated with various concentrations of
SP600125 (A) or PD98059 (B) for 60 min, and then stimulated with 10 ng/ml IL-1b (closed circle) or vehicle (open circle) for 36 h in the
presence of SP600125 or PD98059. Each value represents the mean ± SD of triplicate independent determinations of a representative
experiment carried out three times. Similar results were obtained with two additional and different cell preparations. *P < 0.05 in comparison to
the value of IL-1b alone.
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Figure 4 Effect of JAK inhibitor I on IL-1b-induced IL-6 release.
Cultured cells were pretreated with various concentrations of JAK
inhibitor I for 60 min, and then stimulated with 10 ng/ml IL-1b
(closed circle) or vehicle (open circle) for 36 h in the presence of
JAK inhibitor I. Each value represents the mean ± SD of triplicate
independent determinations of a representative experiment carried
out three times. Similar results were obtained with two additional
and different cell preparations. *P < 0.05 in comparison to the value
of IL-1b alone.
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investigated which pathway is involved in IL-1b-induced
IL-6 release suppression by midazolam. Midazolam
markedly inhibited IL-1b-induced STAT3 phosphoryla-
tion. The inhibitory rate of IL-1b-induced IL-6 levels
caused by midazolam was similar to the inhibitory rate
of IL-1b-induced STAT3 phosphorylation. In contrast,
IB, p38 MAP kinase and SAPK/JNK phosphorylation
were not affected by midazolam. Taking our findings
into account, it is most likely that midazolam inhibits
IL-1b-induced IL-6 release through the JAK/STAT3
pathway suppression in C6 glioma cells.
It has previously been reported that midazolam inhi-
bits N-formyl-methionyl-leucyl-phenylalanine-induced
p38 MAP kinase activation in neutrophils [29], throm-
bin-induced p38 MAP kinase activation in rat cardiac
myocytes [30], and LPS-induced activation of IB-NFB
pathway and p38 MAP kinase in a murine macrophage
cell line [31]. In the present study, we show that mida-
zolam significantly reduces IL-1b-induced STAT3 phos-
phorylation. Seven STAT proteins have been identified
in mammalian cells [25,26]. In the CNS, STAT3 plays
important roles in axonal regeneration and post-
ischemic brain damage [32,33]. It has been reported that
STAT3 activation is necessary for improved axonal
regeneration in the spinal cord after injury [32] and that
the suppression of STAT3 activation induced by brain
ischemia in microglia prevents inflammation and brain
damage [33]. It has been reported that olanzapine, one
of the benzodiazepines, induces phosphorylation of
STAT3 in a rat cortical cell line, resulting in
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Cell extracts were analyzed by Western blotting using antibodies against phospho-specific IB, IB, GAPDH, phospho-specific p38 MAP kinase,
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Figure 6 Effect of midazolam on IL-1b-induced STAT3
phosphorylation. Cultured cells were pretreated with 10 μM
midazolam for 60 min, and then stimulated with 10 ng/ml IL-1b or
vehicle for 60 min in the presence of midazolam. Cell extracts were
analyzed by Western blotting using antibodies against phospho-
specific STAT3 or STAT3. The histogram shows quantitative
representations of the levels of IL-1b-induced phosphorylation of
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with two additional and different cell preparations. *P < 0.05 in
comparison to the value of IL-1b alone.
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While midazolam binds to CBRs and PBRs [4], few
CBRs are expressed in C6 cells [6]. It is known that
PBRs are mainly located in the outer membrane of
mitochondria [2]. Since mitochondria are the source
and target of reactive oxygen species (ROS), it has been
speculated that activation of PBRs suppresses ROS pro-
duction and protects the CNS from ROS-induced
damage [2]. It has recently been reported that a ROS
scavenger inhibits STAT3 activation induced by cerebral
ischemia/reperfusion damage in rats, reduces infarct size
and improves neurological outcomes [35]. Based on
these findings, it is possible that midazolam might inhi-
bit IL-1b-induced STAT3 phosphorylation and IL-6
release through suppression of ROS production via
PBRs. However, the role of STAT3 in benzodiazepine
intracellular signaling in the CNS is not yet clarified.
Further investigation will be required to clarify the sig-
nificance of STAT3 in the CNS.
It is generally known that benzodiazepines modulate
immune system [2,9,10]. In addition, benzodiazepines
reportedly have neuroprotective effects, although to our
knowledge there are no studies indicating better clinical
outcomes [1]. IL-6 is well recognized as a pro-inflam-
matory cytokine and plays a key role in neuroinflamma-
tion [15]. Neuroinflammation accompanies
neurodegenerative diseases and other brain disorders,
such as, for instance, hypoxia/ischemia, traumatic brain
injury, infections and epileptic seizures [15]. It is possi-
ble that midazolam might show neuroprotective effects
through suppression of IL-6 levels in brain. In our pre-
sent study, propofol, another intravenous anesthetic,
failed to affect IL-1b-induced IL-6 release from C6 cells.
Propofol is also suggested to affect the immune system
[36,37] and to have neuroprotective effects in experi-
mental conditions [38]. To the best of our knowledge,
however, there are no reports regarding propofol effects
on the CNS immune system. Based on our findings, it
seems unlikely that the neuroprotective effect of propo-
fol is due to suppression of IL-6 release from glial cells.
IL-6 is expressed in the CNS in basal conditions, sug-
gesting that IL-6 has a crucial role in normal physiolo-
gical processes [15]. Recently, IL-6 has been reported to
have anti-inflammatory properties in addition to pro-
inflammatory roles in the CNS as follows: IL-6 enhances
neuronal differentiation and promotes the survival of
several types of neurons [15]. At the present time, IL-6
is considered to have both advantageous and disadvan-
tageous effects in the CNS, and also to be a valid thera-
peutic target for the treatment of CNS disorders.
Intravenous anesthetics are given to patients under var-
ious conditions such as brain injury, ischemia, neurode-
generative diseases and neuroinflammation. Midazolam
might have an influence in patients with elevated IL-6
levels in the CNS; however, the exact clinical effects are
not clear. It has been reported that blood concentra-
tions of midazolam reach as much as 1.9 μMa f t e ra
bolus injection [39]. The suppressive effect of midazo-
lam on IL-6 release that we find in the present study
was observed at concentrations over 0.3 μM. Therefore,
it seems likely that immunomodulation of the CNS by
midazolam might occur in clinical use. Further investi-
gation is necessary to elucidate anesthetics’ effects on
immune system systemically or by organ, including the
CNS.
In conclusion, our findings strongly suggest that mida-
zolam inhibits IL-1b-induced IL-6 release in rat C6
glioma cells via suppression of STAT3 activation. It is
possible that midazolam may affect immune system
function in the CNS.
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